keyword
MENU ▼
Read by QxMD icon Read
search

Nab paclitaxel

keyword
https://www.readbyqxmd.com/read/29651946/neoadjuvant-therapy-is-essential-for-resectable-pancreatic-cancer
#1
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Shuo Li, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
BACKGROUND: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. METHODS: In this review, we examined available data on neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials...
April 12, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29651809/development-of-chemotherapy-and-significance-of-conversion-surgery-after-chemotherapy-in-unresectable-pancreatic-cancer
#2
REVIEW
Junji Furuse, Junji Shibahara, Masanori Sugiyama
While surgery currently remains the only potentially curative treatment available for pancreatic cancer, only 20% to 30% of patients have resectable disease at diagnosis. Recently, with the introduction of intensive chemotherapy regimens such as oxaliplatin, irinotecan, fluorouracil plus leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel, for the treatment of unresectable pancreatic cancer, the antitumor activity and overall survival in patients with pancreatic cancer have dramatically improved. These advances in intensive chemotherapy have led to the possibility of conversion of unresectable disease to resectable disease, and it has been reported that more than 20% of pancreatic cancer patients with unresectable locally advanced disease at diagnosis undergo successful conversion surgery after FOLFIRINOX therapy...
April 12, 2018: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/29650939/-a-case-of-successful-treatment-with-gemcitabine-plus-nab-paclitaxel-therapy-for-nonresected-pancreatic-body-cancer-stage-ivb
#3
Jun Kaneko, Ayako Kamiya, Kenta Kobayashi, Yasushi Takatsuno, Ito Kondoh, Kentaro Maejima, Jun Isogai, Kumi Hasegawa, Takeshi Endo, Shizuaki Maejima
A 61-year-old woman was introduced for consultation with a chief complaint of frequent vomiting. CT revealed a pancreatic body cancer approximately 40mm in size; an invading stenosis from the horizontal part of the duodenum to the jejunum, superior mesenteric artery, and portal vein, splenic vein obstruction, lymphadenopathy, and some ascitic fluid. We diagnosed a passage disorder due to the invasive stenosis from the horizontal part of the duodenum of the pancreatic body cancer to the jejunum, and subsequently performed a duodenum and jejunum bypass operation...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29644009/pomalidomide-enhanced-gemcitabine-and-nab-paclitaxel-on-pancreatic-cancer-both-in-vitro-and-in-vivo
#4
Nobuhiro Saito, Yoshihiro Shirai, Tadashi Uwagawa, Takashi Horiuchi, Hiroshi Sugano, Koichiro Haruki, Hiroaki Shiba, Toya Ohashi, Katsuhiko Yanaga
Background: Chemotherapy with gemcitabine and nab-paclitaxel (gemcitabine/nab-paclitaxel) is recommended for unresectable pancreatic cancer. However, the therapeutic efficacy is attenuated by the antitumor agent-induced activation of nuclear factor-κB (NF-κB). Thalidomide inhibits NF-κB activation, therefore, we hypothesized that pomalidomide, a third-generation IMiD, would also inhibit NF-κB activation and enhance the antitumor effects of gemcitabine/nab-paclitaxel. Methods: In vitro , we assessed NF-κB activity and apoptosis in response to pomalidomide alone, gemcitabine/nab-paclitaxel, or combination of pomalidomide and gemcitabine/nab-paclitaxel in human pancreatic cancer cell lines (PANC-1 and MIA PaCa-2)...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29621664/chemotherapy-and-radiofrequency-induced-mild-hyperthermia-combined-treatment-of-orthotopic-pancreatic-ductal-adenocarcinoma-xenografts
#5
Martyna Krzykawska-Serda, Mahdi S Agha, Jason Chak-Shing Ho, Matthew J Ware, Justin J Law, Jared M Newton, Lam Nguyen, Steven A Curley, Stuart J Corr
Patients with pancreatic ductal adenocarcinomas (PDAC) have one of the poorest survival rates of all cancers. The main reason for this is related to the unique tumor stroma and poor vascularization of PDAC. As a consequence, chemotherapeutic drugs, such as nab-paclitaxel and gemcitabine, cannot efficiently penetrate into the tumor tissue. Non-invasive radiofrequency (RF) mild hyperthermia treatment was proposed as a synergistic therapy to enhance drug uptake into the tumor by increasing tumor vascular inflow and perfusion, thus, increasing the effect of chemotherapy...
April 2, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29616439/nab-paclitaxel-plus-gemcitabine-versus-folfirinox-as-the-first-line-chemotherapy-for-patients-with-metastatic-pancreatic-cancer-retrospective-analysis
#6
Jihoon Kang, Inhwan Hwang, Changhoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Seung-Mo Hong, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo
Purpose nab-paclitaxel plus gemcitabine (AG) and FOLFIRINOX have been established as standard first-line treatment in metastatic pancreatic cancer (mPC). We performed retrospective analysis comparing the efficacies of AG and FOLFIRINOX in daily practice setting. Materials and Methods We analyzed 308 patients who presented initially as mPC and received AG (n = 149) or FOLFIRINOX (n = 159) as first-line treatment between 2013 and 2016. Primary endpoints were progression-free survival (PFS) and overall survival (OS)...
April 3, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29605174/significant-association-between-low-baseline-neutrophil-to-lymphocyte-ratio-and-improved-progression-free-survival-of-patients-with-locally-advanced-or-metastatic-breast-cancer-treated-with-eribulin-but-not-with-nab-paclitaxel
#7
Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, Hiromi Ozawa, Yukie Fujimoto, Tomoko Higuchi, Arisa Nishimukai, Ayako Kira, Michiko Imamura, Yuichi Takatsuka, Yasuo Miyoshi
INTRODUCTION: Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC. PATIENTS AND METHODS: A total of 85 patients with MBC treated with eribulin (n = 59) or nab-paclitaxel (n = 26) were recruited...
March 8, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29600384/paclitaxel-as-albumin-bound-nanoparticles-with-gemcitabine-for-untreated-metastatic-pancreatic-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#8
REVIEW
Angela Stainthorpe, Janette Greenhalgh, Adrian Bagust, Marty Richardson, Angela Boland, Sophie Beale, Rui Duarte, Eleanor Kotas, Lindsay Banks, Daniel Palmer
As part of the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Celgene Ltd to submit clinical and cost-effectiveness evidence for paclitaxel as albumin-bound nanoparticles (Nab-Pac) in combination with gemcitabine (Nab-Pac + Gem) for patients with untreated metastatic pancreatic cancer. The STA was a review of NICE's 2015 guidance (TA360) in which Nab-Pac + Gem was not recommended for patients with untreated metastatic pancreatic cancer...
March 29, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29599680/the-first-case-of-drug-induced-pseudoscleroderma-and-eczema-craquel%C3%A3-related-to-nab-paclitaxel-pancreatic-adenocarcinoma-treatment
#9
Małgorzata Sokołowska-Wojdyło, Joanna Kłudkowska, Berenika Olszewska, Joanna Seredyńska, Wojciech Biernat, Izabela Błażewicz, Alicja Rustowska-Rogowska, Roman J Nowicki
No abstract text is available yet for this article.
February 2018: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29588392/tumor-infiltrating-lymphocytes-and-pd-l1-expression-in-pre-and-post-treatment-breast-cancers-in-the-swog-s0800-phase-ii-neoadjuvant-chemotherapy-trial
#10
Vasiliki Pelekanou, William E Barlow, Zeina Nahleh, Brad Wasserman, Ying-Chun Lo, Marie-Kristin von Wahlde, Daniel F Hayes, Gabriel N Hortobagyi, Julie R Gralow, Debu Tripathy, Peggy L Porter, Borbala Szekely, Christos Hatzis, David L Rimm, Lajos Pusztai
Our aim was to examine the association of pre-treatment tumor infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical trial which randomized patients to bevacizumab+nab-paclitaxel followed by doxorubicin/cyclophosphamide (AC) versus two control arms without bevacizumab (varying sequence of AC and nab-paclitaxel). TILs were assessed in 124 pre- and 62 post-treatment tissues (including 59 pairs)...
March 27, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29577076/neoadjuvant-chemotherapy-considerations-in-triple-negative-breast-cancer
#11
Nicholas McAndrew, Angela DeMichele
The optimal neoadjuvant chemotherapy (NACT) regimen in triple-negative breast cancer (TNBC) has not been clearly defined. Achieving a pathologic complete response (pCR) provides important prognostic information, and, especially in TNBC, is considered a surrogate endpoint for event-free survival. Thus, many neoadjuvant studies in TNBC focus on this as a primary endpoint, and such information may be used for accelerated US Food and Drug Administration approval. Current controversies in the field include: (1) the role of platinum-based compounds; (2) the optimal chemotherapy backbone; and (3) the benefits of additional therapy after surgery...
February 2018: Journal of Targeted Therapies in Cancer
https://www.readbyqxmd.com/read/29575760/analysis-of-the-activity-and-safety-of-weekly-low-dose-bevacizumab-based-regimens-in-heavily-pretreated-patients-with-metastatic-breast-cancer
#12
Xiaoyu Zhai, Ruoxi Hong, Ying Fan, Peng Yuan, Jiayu Wang, Die Sang, Junlin Chen, Chunying Zhao, Kaiping Ou, Fei Ma, Binghe Xu
BACKGROUND: Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous therapies. METHODS: Seventeen patients with MBC who were heavily pretreated with a median of five regimens of therapy (range 1-10) between 2012 and 2016 were included in the analysis...
March 25, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29564179/the-nab-paclitaxel-gemcitabine-regimen-for-patients-with-refractory-advanced-pancreatic-adenocarcinoma
#13
Sofia Palacio, Peter J Hosein, Isildinha Reis, Ikechukwu I Akunyili, Vinicius Ernani, Terri Pollack, Jessica Macintyre, Maria H Restrepo, Jaime R Merchan, Caio M Rocha Lima
The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab -paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy of the AG combination has not been systematically studied as second-line therapy or beyond for metastatic PC. We conducted an IRB-approved retrospective analysis of all patients diagnosed between September 2010 and August 2014 with advanced refractory PC that received combination treatment with AG at our institution...
February 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29563772/combination-therapy-versus-gemcitabine-monotherapy-in-the-treatment-of-elderly-pancreatic-cancer-a-meta-analysis-of-randomized-controlled-trials
#14
Jiamin Jin, Chunbo Teng, Tao Li
Purpose: We aimed to compare the efficacy of combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer (PC) by using a meta-analysis. Materials and methods: Databases were searched to identify relevant clinical trials. Hazard ratios (HRs) were used to estimate overall survival (OS) and progression-free survival (PFS). Statistical analyses were conducted by using Comprehensive Meta Analysis software (version 2.0). Results: A total of 3,401 elderly PC patients from six randomized controlled trials were included for analysis...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29557103/chemotherapy-and-radiotherapy-for-advanced-pancreatic-cancer
#15
REVIEW
Venessa Chin, Adnan Nagrial, Katrin Sjoquist, Chelsie A O'Connor, Lorraine Chantrill, Andrew V Biankin, Rob Jpm Scholten, Desmond Yip
BACKGROUND: Pancreatic cancer (PC) is a highly lethal disease with few effective treatment options. Over the past few decades, many anti-cancer therapies have been tested in the locally advanced and metastatic setting, with mixed results. This review attempts to synthesise all the randomised data available to help better inform patient and clinician decision-making when dealing with this difficult disease. OBJECTIVES: To assess the effect of chemotherapy, radiotherapy or both for first-line treatment of advanced pancreatic cancer...
March 20, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29556385/phase-i-study-of-third-line-palliative-chemotherapy-with-low-dose-paclitaxel-for-pancreatic-cancer
#16
Hidehiro Tajima, Mitsuyoshi Okazaki, Takahisa Yamaguchi, Yoshinao Ohbatake, Koichi Okamoto, Shinichi Nakanuma, Shiro Terai, Seisho Sakai, Jun Kinoshita, Isamu Makino, Keishi Nakamura, Hironori Hayashi, Katsunobu Oyama, Masafumi Inokuchi, Tomoharu Miyashita, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The present study conducted a Phase I clinical trial of weekly low-dose PTX as a third-line palliative chemotherapy for patients with pancreatic cancer. PTX was administered on days 1, 8, 15, and 22 of each cycle, repeated twice as follows: Level 1, 40 mg/m2 (n=6); Level 2, 50 mg/m2 (n=4)...
April 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29549161/dual-inhibition-of-igf-1r-and-erbb3-enhances-the-activity-of-gemcitabine-and-nab-paclitaxel-in-preclinical-models-of-pancreatic-cancer
#17
Adam J Camblin, Emily A Pace, Sharlene Adams, Michael D Curley, Victoria Rimkunas, Lin Nie, Gege Tan, Troy Bloom, Sergio Iadevaia, Jason Baum, Charlene Minx, Akos Czibere, Chrystal U Louis, Daryl C Drummond, Ulrik B Nielsen, Birgit Schoeberl, J Marc Pipas, Robert M Straubinger, Vasileios Askoxylakis, Alexey A Lugovskoy
PURPOSE: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic cancer pathophysiology, promoting cancer cell survival and therapeutic resistance. Assessment of IGF-1R inhibitors in combination with standard-of-care chemotherapy, however, failed to demonstrate significant clinical benefit. The aim of this work is to unravel mechanisms of resistance to IGF-1R inhibition in pancreatic cancer and develop novel strategies to improve the activity of standard-of-care therapies...
March 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29547556/update-in-systemic-and-targeted-therapies-in-gastrointestinal-oncology
#18
Nelson S Yee
Progress has been made in the treatment of gastrointestinal cancers through advances in systemic therapies, surgical interventions, and radiation therapy. At the Multi-Disciplinary Patient Care in Gastrointestinal Oncology conference, the faculty members of the Penn State Health Milton S. Hershey Medical Center presented a variety of topics that focused on this sub-specialty. This conference paper highlights the new development in systemic treatment of various malignant diseases in the digestive system. Results of the recent clinical trials that investigated the clinical efficacy of pegylated hyaluronidase, napabucasin, and L-asparaginase in pancreatic carcinoma are presented...
March 16, 2018: Biomedicines
https://www.readbyqxmd.com/read/29532546/adjuvant-continuous-metronomic-adriamycin-cyclophosphamide-followed-by-weekly-nab-paclitaxel-for-high-risk-early-stage-breast-cancer
#19
Eunpi Cho, Qian Wu, Lena Rubinstein, Hannah Linden, Julie Gralow, Jennifer Specht, Vijayakrishna Gadi, Georgiana Ellis
Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early-stage breast cancer. Here, we assessed the use of continuous metronomic weekly doxorubicin plus daily oral cyclophosphamide (AC) with continuous G-CSF growth factor support for 12 weeks followed by weekly nab-paclitaxel (nP) for 12 weeks. A nonrandomized phase II clinical trial was designed to assess (1) DFS at 2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities. The dosing of A was 24 mg/m2 IV weekly and C was 60 mg/m2 oral daily (with scheduled filgrastim 5mcg/kg 6 days/week); nP, 100 mg/m2 IV weekly...
March 13, 2018: Breast Journal
https://www.readbyqxmd.com/read/29527313/a-randomised-controlled-trial-of-gemcitabine-hydrochloride-plus-s-1-combination-therapy-versus-gemcitabine-hydrochloride-therapy-alone-in-pancreatic-cancer-patients-aged-%C3%A2-75-years-a-study-protocol-for-an-open-label-randomised-feasibility-study
#20
Hiroshi Ishii, Natsumi Yamashita, Makoto Ueno, Shinichi Ohkawa, Akiko M Saito, Mitsugu Sekimoto
Introduction: In Japan, the age of patients with pancreatic cancer has increased. Combination chemotherapies such as 5-fluorouracil/leucovorin, oxaliplatin and irinotecan therapy and gemcitabine hydrochloride (GEM) +nab paclitaxel therapy have been developed as the standard treatments for young patients with advanced recurrent pancreatic cancer. However, both therapies produce toxicity and their administration is limited by the patients' age or performance status. The efficacy and safety data obtained in the GEST study-a large-scale randomised controlled study conducted in patients with pancreatic cancer in Japan-suggested that GEM +S-1 (GS) combination therapy is a promising candidate for those aged between 75 and 80 years...
2018: BMJ Open Gastroenterology
keyword
keyword
84689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"